FDA issues safety alert on temporary artificial heart

Aug 20, 2018 - 01:54 PM
FDA-warning

The Food and Drug Administration Aug. 17 issued a safety alert after reviewing the final results from a post-approval study conducted by SynCardia Systems for their Temporary Total Artificial Heart (TAH-t) Companion 2 Driver System. SynCardia’s TAH-t functions as a bridge to a heart transplant in a small population of heart failure patients with severe bi-ventricular failure. The study results indicate a higher mortality rate and higher stroke rate for patients initially supported with the C2 Driver System compared to patients initially supported with the previous generation driver – the Circulatory Support System Console – FDA said. “We recommend that you carefully consider these mortality and stroke results from the TAH-t post-approval study when making treatment decisions, and discuss the risks and benefits of the C2 Driver System with patients,” FDA said in a letter to providers. FDA also encourages providers to report any adverse events or suspected adverse events experienced with the SynCardia TAH-t and Driver Systems.

Related News Articles

Headline
AHA celebrates Patient Safety Awareness Week 
March 8-14 marks Patient Safety Awareness Week. The AHA has several resources including podcasts, videos and reports that show how AHA members are advancing…
Headline
Florida district court rules Leapfrog used deceptive practices for hospital safety rating system
The U.S. District Court for the Southern District of Florida March 6 ruled in favor of five Florida hospitals in a case challenging the methodology used by the…
Headline
CDC says infant botulism outbreak is over
The Centers for Disease Control and Prevention Feb. 26 announced that an infant botulism outbreak that sickened 48 babies who consumed ByHeart formula is over…
Headline
South Carolina measles outbreak at 876 cases
The measles outbreak in South Carolina has increased to 876 cases, the state’s Department of Public Health reported Feb. 3. Last week, the South Carolina…
Headline
FDA issues most serious recall for certain glucose monitor sensors
The Food and Drug Administration has identified a Class I recall of certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus…
Headline
AHA podcast: How Safer Care Is Built at Scale
Thomas McGinn, M.D., senior executive vice president and chief physician executive officer at CommonSpirit Health, shares how the organization aligns…